Alerta

SPIKE FURIN CLEAVAGE IS A SARS-COV-2 TARGETING STRATEGY TO BREAK THE CHAIN OF INFECTION CYCLE

Resumen de: US2025179151A1

Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.

SARS-COV-2 NEUTRALIZING SYNTHETIC PROTEINS

Resumen de: US2025179152A1

The present disclosure relates to compositions and methods for the treatment and/or prevention of SARS-COV-2 infections. In one embodiment the method comprises the delivery of a pharmaceutical composition comprising a SARS-COV-2 neutralizing synthetic protein, optionally wherein the protein is a trimeric protein composed of designed ankyrin repeat protein (DARPin) fused with a T4 foldon peptide that is administered non-invasively such as by nasal inhalation.

SANGUISORBA OFFICINALIS LINNE EXTRACT COMPOSITION INHIBITING 3CL PROTEASE AND RDRP ACTIVITY OF SARS-COV-2

Resumen de: US2025177469A1

The present invention relates to a use of a novel Sanguisorba officinalis Linne extract to inhibit SARS-CoV-2 virus 3CL protease and RdRp activity. The composition including the Sanguisorba officinalis Linne extract of the present invention as an active ingredient inhibits 3CL protease and RdRp activity and thus is effective in preventing or treating infection by SARS-CoV-2 and a variant virus thereof.

Vaccine compositions for mucosal immune response

Resumen de: AU2025203389A1

Abstract A vaccine composition comprising a lyophilized, adenovirus-based expression vector encoding a disease antigen, and a stabilizing compound, such as aragonite. The disease antigen may comprise a viral protein or fragment thereof, such as a SARS-CoV2 virus protein. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.

Real-Time Contactless Bio-Threat Screening

Resumen de: US2025180506A1

This present invention provides a system, method, and device for rapidly screening individuals at a high rate of speed. The invention features a method, system and device that analyzes an individual's body odors to determine the presence or absence of a disease such as COVID-19 and/or its variants. The invention allows for real-time testing for a pathogen, a disease, or other condition of interest that is especially useful when testing every individual entering or exiting a venue or transitioning through any controlled entry or exit zone demarcated by a portal, passage, security zone, or gate, etc. This testing requires no invasive sampling—or even touch contact—between the device or device operator and the person being tested. The device features a sensing surface whose electronic activity is a function volatile organic compounds (body odor) in the immediate vicinity of its surface.

PEGYLATED SERP-1 PROTEIN TREATMENT IMPROVES OUTCOMES AFTER SARS-COV-2 INFECTION

Resumen de: US2025177541A1

Disclosed herein are methods of treating a lung disorder. In some embodiments, the lung disorder includes an acute respiratory syndrome. In some embodiments, the treatment includes administering to a subject in need thereof, a modified Serp-1 protein. The modified Serp-1 protein may include a therapeutic enhancing moiety. In some embodiments, the therapeutic enhancing moiety is a water soluble polymer such as polyethylene glycol.

COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19

Resumen de: US2024166587A1

The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.

Crystal forms of an anti-sars cov-2 agent

Resumen de: AU2023356620A1

The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

Treatment using a one-to-stop attenuated sars-cov-2 virus

Resumen de: AU2023361023A1

The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

FORMULATION OF AN INHALABLE QUERCETIN SOLUTION FOR THE MANAGEMENT OF RESPIRATORY DISEASES

Resumen de: WO2025108530A1

The present invention describes the formulation of a phytotherapy product, namely an inhalable solution developed from a natural extract of quercetin, either alone or in combination with resveratrol, rigorously selected for their synergistic effects on the respiratory system and their potential in alleviating symptoms associated with respiratory diseases such as asthma, COPD, lung cancer, COVID-19, and long COVID. The solution is intended to be inhaled using a nebuliser or other inhalation device intended to transform the solution into an aerosol in order to have a direct effect on the bronchi and minimise side effects. Quercetin has anti-inflammatory, antioxidant, immunomodulatory, and antiviral properties. This document describes, through various examples, the manufacturing process developed to obtain a solution for inhalation.

SMALL PEPTIDES FOR INHIBITING SARS-COV-2 SPIKE PROTEIN-AND LPS-INDUCED INFLAMMATION AND CYTOKINE PRODUCTION

Resumen de: WO2025111412A1

Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).

VZV ANTIGEN VARIANT, NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Resumen de: WO2025108306A1

Disclosed are a VZV antigen variant, a nucleic acid, a pharmaceutical composition and the use thereof. The VZV antigen variant has a difference of Y582G compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has deletions at positions 561-623, 569-623 or 574-623 compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has a modification of a transmembrane region and intracellular region of a protein compared to an amino acid sequence as set forth in SEQ ID NO: 1, wherein the modification of the transmembrane region and intracellular region of the protein involves the replacement of a transmembrane region and intracellular region of an original VZV antigen with a transmembrane region of a SARS-CoV-2Spike protein or a transmembrane region of an influenza H protein. The VZV antigen variant has a stronger immunogenicity than the VZV antigen in the prior art, can achieve a higher titer of binding antibodies, and has a higher protection efficacy.

OPTIMIZED SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS AND COMPOSITIONS COMPRISING THE SAME

Resumen de: WO2025109176A1

This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV- 1, and affinity matured variants thereof. The binding agents, in particular the antibodies and antibody fragments, have one or more favourable antibody development characteristics. The invention also relates to methods using these binding agents and uses thereof.

RAPID METHOD FOR ROOM TEMPERATURE REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (RT-LAMP) AND REAGENT KIT

Resumen de: US2025171864A1

The present invention relates to a rapid method to perform reverse transcription loop-mediated isothermal amplification (RT-LAMP) and LAMP at room temperature between 25-42° C., more specifically at 25-37° C., to detect RNA/DNA in a sample and a reagent kit thereof. Further, the invention relates to an in vitro method to detect SARS-CoV2 using RT-LAMP at room temperature between 25-42° C., more specifically at 37° C. The reagent kit comprises of enzymes/proteins—Klenow exo−/−, ApaI, High fidelity Taq Pol, Rpa32, StpA, AMV-RT for reverse transcriptase; buffer composition of—Tris-HCl, MgSO4, KCl, DTT, PEG, DMSO, 1 mM dNTPs each, at least 4 primers, and fluorescent or colorimetric dye.

ACTION OF L-CITRULLINE TO PREVENT OR TREAT ENDOTHELIAL DYSFUNCTION

Resumen de: US2025170084A1

This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.

CDP-CHOLINE A HOST-DIRECTED THERAPEUTIC FOR DISEASE CAUSED BY SARS COV-2 INFECTION

Resumen de: US2025170246A1

Compositions and methods are disclosed for treating coronavirus infections, such as SARS CoV-2 coronavirus infections. For example, a composition is disclosed that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDP-ethanolamine (CDP-ETH), and CDPdiacylglycerol (CDP-DAG) in combination with one or more agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals, in a pharmaceutically acceptable carrier. Also disclosed is a method of treating coronavirus (e.g. SARS CoV-2) infection in a subject that involves administering to the subject one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDPethanolamine (CDP-ETH), and CDP-diacylglycerol (CDP-DAG) in combination with agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals.

COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), INFLUENZA A AND INFLUENZA B

Resumen de: US2025171862A1

Methods for the rapid detection of the presence or absence of SARS-CoV-2, influenza A and influenza B in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2, influenza A, and influenza B and kits are provided that are designed for the detection of SARS-CoV-2, influenza A and influenza B.

DEVICE TO CLOSE TOILET LID BEFORE FLUSHING

Resumen de: US2025169661A1

Device to close a toilet lid before flushing contains a base part (2) in which a drive device in form of an electrical motor (7) is situated. On top of the base part (2) a motion detector (5) is located that controls a movable arm (3). Within the base part a motherboard (6) is situated. With help from the movement that emerge when flushing the motion detector (5) is activated, that in turn activates the electrical motor (7) that is connected with the movable arm (3) on the front side of the base part (2). The arm (3) opens up 45 degrees, pushes the toilet lid and returns to the origin mode. The detector (4) senses that the lid is no longer resting against the base part (2) and shuts of the device (1). In this way the source of the power consumption, which is a rechargeable battery (3), is limited. The lid is closed completely before flushing and bacteria, virus and the spread of Covid 19 is reduced.

N4-ISOBUTYRYLOXYCYTIDINE ANALOG SYNTHESIS AND COMPOSITION FOR TREATING VIRAL INFECTION COMPRISING ANTI-VIRAL USE THEREOF

Resumen de: US2025171486A1

The present disclosure relates to N4-isobutyryloxycytidine analog synthesis and to the anti-viral use thereof against dengue virus, influenza virus, and SARS-COV-2 virus.

TRYPTANTHRIN DERIVATIVES WITH THIOSEMICARBAZONE SUBSTITUTION AND USE THEREOF

Resumen de: US2025171449A1

The invention relates to tryptanthrin derivatives with thiosemicarbazone substitution of the general formulae I and II, where R1-R8 are independently H, OH, alkyl with 1 to 6 carbon atoms, C(CH3)3, allyl, propargyl, ben-zyl, phenyl, F, Cl, Br, I, CH2OH, O (alkyl), CF3, OCF3, CN, COOH, COO(alkyl), CONH2, CONH(alkyl), NO2, N(alkyl)2, NH(alkyl), NHCO(alkyl), where the alkyl has 1 to 6 carbon atoms, or R1-R2 or R2-R3 or R3-R4 or R5-R6 or R6-R7 or R7-R8 is —CH═CH—CH═CH—, i.e., a fused benzene ring, X and Z are independently H, alkyl of 1 to 6 carbon atoms, benzyl or phenyl. The compounds combine a structural motif suitable for PLpro targeting, have strong affinity and selectivity for RNA over DNA, and at the same time effectively chelate ferric and ferrous ions. Thus, these compounds have the desired properties for potential use as inhibitors of the production of SARS-COV-2 viral particles and can thus be used for the preparation drugs for the treatment of coronavirus diseases, especially COVID-19.

ANTIVIRAL PEPTIDES AND METHODS OF USE THEREOF

Resumen de: US2025171511A1

Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.

DUPILUMAB FOR TREATMENT OF COVID-19

Resumen de: US2025171546A1

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.

ENVELOPED VIRUS LIKE PARTICLES COMPRISING SARS-COV-2 S PROTEIN

Resumen de: WO2024018364A1

Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.

COVID-19 AND RESPIRATORY DISEASE VIRUS INFECTION MODELS USING LUNG ORGANOIDS

Resumen de: EP4560010A1

The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.

METHOD FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) DETECTION ON BASIS OF RECEPTOR BINDING

Nº publicación: ZA202407723B 28/05/2025

Solicitante:

CENTRAL HOSPITAL OF MINHANG DISTR SHANGHAI [CN]
CENTRAL HOSPITAL OF MINHANG DISTRICT SHANGHAI

Resumen de: ZA202407723B

The present disclosure provides a method for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection on the basis of receptor binding, including: subjecting crosslinked agarose as a matrix to surface carboxyl modification to obtain a magnetic agarose microsphere, and covalently coupling the magnetic agarose microsphere with a receptor protein to obtain a receptor protein-coupled magnetic agarose microsphere; allowing the receptor protein covalently binding to a surface of the receptor protein-coupled magnetic agarose microsphere to recognize and bind to a receptor-binding domain (RBD) of an outer membrane protein S of a SARS-CoV-2 sample, which simulates a binding process of the SARS-CoV-2 to a host cell to capture the SARS-CoV-2; subjecting the magnetic microsphere to washing, purification, and elution successively to obtain the SARS-CoV-2 with a cell binding ability; and detecting by an immunobinding-fluorescence quantitative polymerase chain reaction (PCR) combination, and evaluating infectivity and transmissibility of the SARS-CoV-2. The method is suitable for evaluating the replication and transmission of the SARS-CoV-2 in a patient infected with the SARS-CoV-2 during a treatment process and the infectivity of the SARS-CoV-2 carried by a patient with relapse symptoms after recovery.